Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Multiple Myeloma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Ganglioneuroblastoma 1Adenoma, Islet Cell 1

Interventions

Nivolumab 21pembrolizumab 19Ipilimumab 14Specimen Handling 12Magnetic Resonance Spectroscopy 7Opdualag 6CTLA-4 Antigen 6relatlimab 5binimetinib 5trametinib 4Paclitaxel 4dabrafenib 3Taxes 3Standard of Care 3Pemetrexed 3Introns 3Interferon alpha-2 3Gemcitabine 3Carboplatin 3Blood Specimen Collection 3ulixertinib 2sargramostim 2lifileucel 2lenvatinib 2fludarabine phosphate 2fludarabine 2encorafenib 2capivasertib 2cabozantinib 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Colony-Stimulating Factors × 30 days × Clear all
NCT01134614 2026-05-29

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
245 enrolled 8 charts
Dermatologic

Melanoma

NCT02339571 2026-05-29

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡